rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Vuong Trieu

Chairman and CEO

Company insider

Files Form 4 as: Chairman and CEO, Mateon Therapeutics; Executive Chairman, Marina Biotech; Cso, Sorrento Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
73
Buys
32
Sells
0
Bought
$455K
Sold
$0
Companies
3
Companies where not an officer
0
First trade
29 Oct 2013
Last trade
29 Oct 2026
Last filed
30 Oct 2026

Companies traded

Where they are an officer
Mateon TherapeuticsDirector, Officer, 10% owner · Biotechnology · last 29 Oct 202628 buys · 0 sells
Marina BiotechDirector, Officer, 10% owner · last 1 Oct 20184 buys · 0 sells
Sorrento TherapeuticsDirector, Officer · last 29 Oct 20130 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
06Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
29 Oct 2026filed 30 Oct 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$18K1,044,990 at $0.017filing
28 Oct 2026filed 30 Oct 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$5,772312,000 at $0.0185filing
10 Jul 2026filed 14 Jul 2026Mateon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—2,000 at $0.00filing
10 Jul 2026filed 14 Jul 2026Oncotelic Therapeuticsoption or derivativeSEC FORM 4 Code A—2,000 at $0.00filing
1 Jul 2026filed 2 Jul 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$10K240,000 at $0.0431filing
1 Jul 2026filed 2 Jul 2026Oncotelic TherapeuticsSEC FORM 4 Bought$9,600240,000 at $0.04filing
24 Jun 2026filed 24 Jun 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$5,175115,000 at $0.045filing
24 Jun 2026filed 24 Jun 2026Oncotelic TherapeuticsSEC FORM 4 Bought$5,750115,000 at $0.05filing
23 Jun 2026filed 24 Jun 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$3,37575,000 at $0.045filing
23 Jun 2026filed 24 Jun 2026Oncotelic TherapeuticsSEC FORM 4 Bought$3,75075,000 at $0.05filing
22 Jun 2026filed 24 Jun 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$2,92565,000 at $0.045filing
22 Jun 2026filed 24 Jun 2026Oncotelic TherapeuticsSEC FORM 4 Bought$3,25065,000 at $0.05filing
17 Jun 2026filed 17 Jun 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$11K239,759 at $0.0446filing
17 Jun 2026filed 17 Jun 2026Oncotelic TherapeuticsSEC FORM 4 Bought$9,590239,759 at $0.04filing
15 Jun 2026filed 17 Jun 2026Mateon TherapeuticsBiotechnologySEC FORM 4 Bought$4,32096,000 at $0.045filing
15 Jun 2026filed 17 Jun 2026Oncotelic TherapeuticsSEC FORM 4 Bought$4,80096,000 at $0.05filing
22 Jan 2026filed 26 Jan 2026Mateon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—4,426 at $0.00filing
22 Jan 2026filed 26 Jan 2026Oncotelic Therapeuticsoption or derivativeSEC FORM 4 Code A—4,426 at $0.00filing
17 Nov 2025filed 19 Nov 2025Oncotelic Therapeuticsoption or derivativeSEC FORM 4 Code A—4,065 at $0.00filing
10 Jul 2025filed 10 Jul 2025Oncotelic TherapeuticsSEC FORM 4 Bought$1,040104,000 at $0.01filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care8
Not placed30

Buys in green, sells in red, by the company’s sector.

Related people

Seymour Howard FeinCro/Cmo · Cro/Cmo at Oncotelic Therapeutics, filing Form 4 there in the last year
Steven W. KingDirector · Director at Oncotelic Therapeutics, filing Form 4 there in the last year
Anthony E. Maida IIIDirector and Cmo - Trans. Med. · Director and Cmo - Trans. Med. at Oncotelic Therapeutics, filing Form 4 there in the last year
Amit B. ShahCFO · CFO at Oncotelic Therapeutics, filing Form 4 there in the last year
Saran SaundCbo · Cbo at Oncotelic Therapeutics, filing Form 4 there in the last year